$百时美施贵宝(BMY)$ 希望以此为契机，开始新征程！！$Sutro Biopharma(STRO)$ 也是好票

Bristol-Myers receives FDA’s orphan drug designation for multiple myeloma therapy

Yesterday, the FDA has granted an orphan drug designation to Bristol-Myers Squibb (BMY +3.1%) for an experimental therapy targeting multiple myeloma.The FDA’s Orphan Drug product website identifies the candidate as an ‘antibody drug conjugate (“ADC”) comprised of an anti-B cell maturation (“BCMA”) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (“DBCO”) non cleavable linker maytansinoid warhead.’The BCMA antibody-drug conjugate to receive the FDA designation is believed to be CC-99712, a collaboration of Bristol-Myers with Sutro Biopharma (STRO +5.3%).According to Sutro’s latest 10Q filing, the enrollment for a Phase 1 trial for CC-99712 has started and Bristol-Myers has worldwide development and commercialization rights for the experimental therapy.